RANOLAZINE

Search structure
Trade Names:
Synonyms:
Status: Approved (2006)
Entry Type: Small molecule
Molecule Category: UNKNOWN
ATC: C01EB18
UNII: A6IEZ5M406

Structure
InChI Key XKLMZUWKNUAPSZ-UHFFFAOYSA-N
Smile COc1ccccc1OCC(O)CN1CCN(CC(=O)Nc2c(C)cccc2C)CC1
InChI
InChI=1S/C24H33N3O4/c1-18-7-6-8-19(2)24(18)25-23(29)16-27-13-11-26(12-14-27)15-20(28)17-31-22-10-5-4-9-21(22)30-3/h4-10,20,28H,11-17H2,1-3H3,(H,25,29)

Physicochemical Descriptors

Property Name Value
Molecular Formula C24H33N3O4
Molecular Weight 427.55
AlogP 2.31
Hydrogen Bond Acceptor 6.0
Hydrogen Bond Donor 2.0
Number of Rotational Bond 9.0
Polar Surface Area 74.27
Molecular species NEUTRAL
Aromatic Rings 2.0
Heavy Atoms 31.0

Pharmacology

Action Mechanism of Action Reference
BLOCKER Sodium channel protein type IV alpha subunit blocker PubMed
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Enzyme Kinase Protein Kinase AGC protein kinase group AGC protein kinase PKC family AGC protein kinase PKC iota subfamily
- 6900 - - -
Ion channel Voltage-gated ion channel Potassium channels Voltage-gated potassium channel
- 12000 - - -
Ion channel Voltage-gated ion channel Voltage-gated sodium channel
- - - - 11-19
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC21/SLCO family of organic anion transporting polypeptides
- - - - -15-83

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Angina, Stable 4 D060050 ClinicalTrials
Coronary Disease 3 D003327 ClinicalTrials
Diabetes Mellitus, Type 2 3 D003924 ClinicalTrials
Atrial Fibrillation 3 D001281 ClinicalTrials
Myocardial Ischemia 3 D017202 ClinicalTrials
Long QT Syndrome 2 D008133 ClinicalTrials
Vascular Diseases 2 D014652 ClinicalTrials
Irritable Bowel Syndrome 2 D043183 ClinicalTrials
Cardiomyopathy, Dilated 2 D002311 ClinicalTrials
Heart Failure, Diastolic 2 D054144 ClinicalTrials
Acute Coronary Syndrome 2 D054058 ClinicalTrials
Amyotrophic Lateral Sclerosis 2 D000690 ClinicalTrials
Crohn Disease 2 D003424 ClinicalTrials
Kidney Diseases 1 D007674 ClinicalTrials
Myotonic Disorders 1 D020967 ClinicalTrials
Hypertension, Pulmonary 1 D006976 ClinicalTrials

Related Entries

MCS

Side Effects from Label

Adverse Reactions

SOC By Demographic Distribution
System Organ Classification (SOC)
Relative Frequency (%)
Cardiac disorders
14.52
Vascular disorders
11.69
Nervous system disorders
11.66
General disorders and administration site conditions
10.87
Injury, poisoning and procedural complications
7.17
Respiratory, thoracic and mediastinal disorders
6.32
Surgical and medical procedures
6.32
Gastrointestinal disorders
5.33
Psychiatric disorders
4.15
Musculoskeletal and connective tissue disorders
3.14
Investigations
2.94
Skin and subcutaneous tissue disorders
2.3
Metabolism and nutrition disorders
2.08

Cross References

Resources Reference
CAS NUMBER 95635-55-5
ChEBI 87690
ChEMBL CHEMBL1404
DrugBank DB00243
DrugCentral 2359
EPA CompTox DTXSID3045196
FDA SRS A6IEZ5M406
Human Metabolome Database HMDB0014388
Guide to Pharmacology 7291
PharmGKB PA164746007
PubChem 56959
SureChEMBL SCHEMBL124665
CONTENTS